These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 26154342)

  • 21. Synthesis of mannosylated glycopeptides as components for synthetic vaccines.
    Kowalczyk R; Brimble MA; Dunbar R
    Adv Exp Med Biol; 2009; 611():351-2. PubMed ID: 19400222
    [No Abstract]   [Full Text] [Related]  

  • 22. Self-Assembled Nano-Immunostimulant for Synergistic Immune Activation.
    Sun ZY; Chen PG; Liu YF; Shi L; Zhang BD; Wu JJ; Zhao YF; Chen YX; Li YM
    Chembiochem; 2017 Sep; 18(17):1721-1729. PubMed ID: 28618135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hybrid nanoparticle-based nicotine nanovaccines: Boosting the immunological efficacy by conjugation of potent carrier proteins.
    Zhao Z; Hu Y; Harmon T; Pentel PR; Ehrich M; Zhang C
    Nanomedicine; 2018 Jul; 14(5):1655-1665. PubMed ID: 29719216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine carriers.
    Xiang SD; Wilson K; Day S; Fuchsberger M; Plebanski M
    Methods; 2013 May; 60(3):232-41. PubMed ID: 23643867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of vaccine adjuvants incorporating TNF superfamily ligands and TNF superfamily molecular mimics.
    Gupta S; Termini JM; Kanagavelu S; Stone GW
    Immunol Res; 2013 Dec; 57(1-3):303-10. PubMed ID: 24198065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges.
    Ahmad MZ; Ahmad J; Haque A; Alasmary MY; Abdel-Wahab BA; Akhter S
    Expert Rev Vaccines; 2020 Nov; 19(11):1053-1071. PubMed ID: 33315512
    [No Abstract]   [Full Text] [Related]  

  • 27. mRNA vaccine for cancer immunotherapy.
    Miao L; Zhang Y; Huang L
    Mol Cancer; 2021 Feb; 20(1):41. PubMed ID: 33632261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A self-adjuvanting supramolecular vaccine carrying a folded protein antigen.
    Hudalla GA; Modica JA; Tian YF; Rudra JS; Chong AS; Sun T; Mrksich M; Collier JH
    Adv Healthc Mater; 2013 Aug; 2(8):1114-9. PubMed ID: 23436779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection of potent immunological adjuvants for vaccine construction.
    McElrath MJ
    Semin Cancer Biol; 1995 Dec; 6(6):375-85. PubMed ID: 8938276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent development in carbohydrate-based cancer vaccines.
    Guo Z; Wang Q
    Curr Opin Chem Biol; 2009 Dec; 13(5-6):608-17. PubMed ID: 19766052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gold Nanoparticles as Carriers for Synthetic Glycoconjugate Vaccines.
    Chiodo F; Marradi M
    Methods Mol Biol; 2015; 1331():159-71. PubMed ID: 26169740
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of experimental synthetic peptide immunogens for prevention of HIV-1 and HTLV-I retroviral infections.
    Hart MK; Palker TJ; Haynes BF
    Pharm Biotechnol; 1995; 6():821-45. PubMed ID: 7551251
    [No Abstract]   [Full Text] [Related]  

  • 33. Vaccine technologies: From whole organisms to rationally designed protein assemblies.
    Karch CP; Burkhard P
    Biochem Pharmacol; 2016 Nov; 120():1-14. PubMed ID: 27157411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response.
    Westerlind U; Hobel A; Gaidzik N; Schmitt E; Kunz H
    Angew Chem Int Ed Engl; 2008; 47(39):7551-6. PubMed ID: 18704911
    [No Abstract]   [Full Text] [Related]  

  • 35. Targeting nanoparticles to dendritic cells for immunotherapy.
    Cruz LJ; Tacken PJ; Rueda F; Domingo JC; Albericio F; Figdor CG
    Methods Enzymol; 2012; 509():143-63. PubMed ID: 22568905
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Harnessing self-assembly to enable modular vaccine design.
    Biotechnol Bioeng; 2017 Feb; 114(2):244. PubMed ID: 28005281
    [No Abstract]   [Full Text] [Related]  

  • 37. A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic.
    Wilson RM; Danishefsky SJ
    J Am Chem Soc; 2013 Oct; 135(39):14462-72. PubMed ID: 23944352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthetic vaccines from tumor-associated glycopeptide antigens.
    Westerlind U; Kunz H
    Chimia (Aarau); 2011; 65(1-2):30-4. PubMed ID: 21469441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthetic vaccine nanoparticles target to lymph node triggering enhanced innate and adaptive antitumor immunity.
    Kim SY; Noh YW; Kang TH; Kim JE; Kim S; Um SH; Oh DB; Park YM; Lim YT
    Biomaterials; 2017 Jun; 130():56-66. PubMed ID: 28364631
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CureVac COVID vaccine let-down spotlights mRNA design challenges.
    Dolgin E
    Nature; 2021 Jun; 594(7864):483. PubMed ID: 34145413
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.